

ZFW 1615



PATENT
Attorney Docket No. 056291-5174-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GELLERT *et al.*

Application No.: 10/505,231

Filed: August 19, 2004

For: PHARMACEUTICAL FORMULATION OF
IRESSA COMPRISING A WATER-SOLUBLE
CELLULOSE DERIVATIVE

Group Art Unit: 1615

Examiner: Unassigned

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Documents 1, 11, 24 and 28 were cited in an International Search Report which issued in a corresponding PCT application PCT/GB03/00803, a copy of which is attached for the Examiner's convenience. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior

art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a
CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.
§1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: July 28, 2005
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION <small>(use several sheets if necessary)</small>		Attorney Docket No. 056291-5174-US	Application No. 10/505,231
		Applicants: GELLERT <i>et al.</i>	PAGE 1 of 2
		Filing Date: August 19, 2004	Group Art Unit: 1615

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	2003/045537	March 6, 2003	Lee et al.			
2.	2002/009494	January 24, 2002	Curatolo et al.			
3.	6,383,471	May 7, 2002	Chen et al.			
4.	6,294,192	September 25, 2001	Patel et al.			
5.	6,248,771	June 19, 2001	Shenoy et al.			
6.	5,631,248	May 20, 1997	Davis et al.			
7.	5,616,582	April 1, 1997	Barker			
8.	5,559,158	September 24, 1996	Al-Razzak et al.			
9.	5,457,105	October 10, 1995	Barker			
10.	4,704,284	November 3, 1987	Beatty et al.			
11.	4,344,934	August 17, 1982	Martin et al.			

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
12.	WO 03/32956	April 24, 2003	WIPO			
13.	WO 03/00294	January 3, 2003	WIPO			
14.	WO 02/89773	November 14, 2002	WIPO			
15.	WO 02/20020	March 14, 2002	WIPO			
16.	WO 02/02534	January 10, 2002	WIPO			
17.	WO 01/76586	October 18, 2001	WIPO			
18.	WO 01/47495	July 5, 2001	WIPO			
19.	WO 01/04102	January 18, 2001	WIPO			
20.	WO 00/59475	October 12, 2000	WIPO			
21.	WO 00/00179	January 6, 2000	WIPO			
22.	WO 98/38984	September 11, 1998	WIPO			
23.	WO 96/38131	December 5, 1996	WIPO			
24.	WO 96/33980	October 31, 1996	WIPO			
25.	EP 1027887	August 16, 2000	EPA			
26.	EP 1027886	August 16, 2000	EPA			
27.	EP 901786	March 17, 1999	EPA			
28.	GB 2,306,885	May 14, 1997	Great Britain			
29.	JP 09059159	March 4, 1997	Japan			Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

30.	Barker et al. "Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" <i>Biorg Med Chem Lett.</i> 11(14): 1911-1914 (2001)
31.	Hasegawa et al. "Supersaturation mechanism of drugs from solid dispersions with enteric coating agents" <i>Chem Pharm Bull (Tokyo)</i> 36(12): 4941-4950 (1988)
32.	Herbst et al. "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial" <i>J Clin Oncol</i> 20(18): 3815-3825 (2002)

Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

